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PRegression of pressure-induced left ventricular hypertrophy is
characterized by a distinct gene expression profile
William E. Stansfield, MD,a Peter C. Charles, PhD,b,c Ru-hang Tang, PhD,a,c Mauricio Rojas, MD,c Rajendra Bhati, MD,a
Nancy C. Moss, MD,a Cam Patterson, MD,b,c and Craig H. Selzman, MDa,c,d
Objective: Left ventricular hypertrophy is a highly prevalent and robust predictor of cardiovascular morbidity
and mortality. Existing studies have finely detailed mechanisms involved with its development, yet clinical trans-
lation of these findings remains unsatisfactory. We propose an alternative strategy focusing on mechanisms of left
ventricular hypertrophy regression rather than its progression and hypothesize that left ventricular hypertrophy
regression is associated with a distinct genomic profile.
Methods:Minimally invasive transverse arch banding and debanding (or their respective sham procedures) were
performed in C57Bl6 male mice. Left ventricular hypertrophy was assessed physiologically by means of trans-
thoracic echocardiographic analysis, structurally by means of histology, and molecularly by means of real-time
polymerase chain reaction. Mouse hearts were genomically analyzed with Agilent (Santa Clara, Calif) mouse 44k
developmental gene chips.
Results: Compared with control animals, animals banded for 28 days had a robust hypertrophic response, as de-
termined by means of heart weight/body weight ratio, histologic analysis, echocardiographic analysis, and fetal
gene expression. These parameters were reversed within 1 week of debanding. Whole-genome arrays on left ven-
tricular tissue revealed 288 genes differentially expressed during progression, 265 genes differentially expressed
with regression, and only 23 genes shared by both processes. Signaling-related expression patterns were more
prevalent with regression rather than the structure-related patterns associated with left ventricular hypertrophy
progression. In addition, regressed hearts showed comparatively more changes in energy metabolism and protein
production.
Conclusions: This study demonstrates an effective model for characterizing left ventricular hypertrophy and re-
veals that regression is genomically distinct from its development. Further examination of these expression pro-
files will broaden our understanding of left ventricular hypertrophy and provide a novel therapeutic paradigm
focused on promoting regression of left ventricular hypertrophy and not just halting its progression.Supplemental material is available online.
Left ventricular hypertrophy (LVH) affects approximately
25% of adult Americans and is most often associated with
pressure overload, as seen with essential hypertension, aortic
stenosis, and ischemic heart disease.1 LVH is highly morbid
and is a robust risk factor for cardiovascular mortality.2 Yet
despite optimal blood pressure control, treated hypertensive
patients rarely achieve more than a 15% to 20% reduction in
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patients will continue to have LVH progression and in-
creased cardiovascular events, including death.3 Thus there
remains a great need to expand our understanding and treat-
ment of LVH.
To date, most experimental and therapeutic approaches
addressing pressure-induced LVH have been directed at its
progression. Numerous studies have profiled the genomic
response to aortic banding at multiple time points,4 in differ-
ent chambers,5 and in different sexes.6 Collectively, these
types of studies have exquisitely detailed and identified
mechanistic targets that can be blocked to delay or restrict
LVH progression7,8 but have not been effective in advancing
therapy for existing disease. As opposed to the plethora of
studies focusing on LVH development, few studies have
attempted to characterize independent features of LVH
regression. Friddle and colleagues9 first detailed genomic
differences with LVH regression using nascent gene array
technology after administration and withdrawal from b-
adrenergic agonists. Although no significant physiologic
differences between groups were discerned, 8 genes unique
to the drug removal were identified. Despite only 4000 genes
on the array platform, this study revealed that gene expres-
sion differences between groups might exist in the absencergery c January 2009
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PAbbreviations and Acronyms
DAVID ¼ Database for Annotation, Visualization,
and Integrated Discovery
Hpcal1 ¼ hippocalin-like 1
Limma ¼ linear models for microarray
LV ¼ left ventricular
LVH ¼ left ventricular hypertrophy
PCR ¼ polymerase chain reaction
Plk1 ¼ polo-like kinase 1
SAFE ¼ Significance Analysis of Functional
Expression
of detectable physiologic changes and that array technology
might be sensitive enough to highlight these differences.
We and others have demonstrated that removal of a previ-
ously placed constrictive aortic band can allow reversal of
LVH.10-12 Similarly, studies of human patients with LVH
who undergo aortic valve replacement for aortic stenosis
are highly successful in causing LVH regression.13 It re-
mains unknown, however, whether LVH regression is truly
a unique process and thus a target for focused study and in-
tervention. Accordingly, we sought to determine whether
gene expression associated with physiologic LVH regres-
sion was not simply the reverse of those genes associated
with LVH progression but rather a distinct genomic pattern.
MATERIALS AND METHODS
Surgical Model and Experimental Design
In accordance with both an institutionally approved Institutional Animal
Care and Use Committee protocol and National Institutes of Health guide-
lines, 10-week-old C57Bl6 male mice were randomly assigned to one of 4
groups: sham, band, sham deband, and deband. The 60 mice enrolled were
partitioned as follows: 10 in the sham group, 15 in the band group, 13 in the
sham deband group, and 21 in the deband group. Mice in the sham and band
groups underwent minimally invasive transverse aortic banding, as previ-
ously described.10 Briefly, animals were anesthetized with inhaled isoflur-
ane administered through a facemask. A midline neck incision was used
to approach the anterior mediastinum. The transverse arch was identified,
and a constrictive band was placed and tightened to the approximate diam-
eter of a 27-gauge needle. The only difference between the sham and band
groups was that in the sham group, the constrictive band was not tightened.
Adequate placement of the band was verified by means of evaluation of ca-
rotid Doppler scans both before and after placement of the aortic band. Ad-
equate banding was accepted when the Doppler velocity ratio doubled from
the right to left carotid arteries. Animals in the deband and sham deband
groups had initial procedures identical to those for the band and sham
groups, respectively. At 4 weeks, the aortic band was removed, heretofore
referred to as being debanded.10 Efficiency of debanding was verified by
means of carotid Doppler scanning with normalization of carotid velocities.
Animals from the deband and sham deband groups were killed 1 week after
the deband procedure for all evaluations except histology, for which animals
were killed both at 1 and 4 weeks after debanding.
Transthoracic Echocardiography
Transthoracic echocardiography was performed with the Vevo 660 High
Resolution Biomicroscopy System equipped with a 30-Mhz transducerThe Journal of Thoracic and C(Visual Sonics, Toronto, Calif). During examination, mice were anesthe-
tized with 1% to 1.5% inhaled isoflurane. The depth of anesthesia was stan-
dardized by recording images at heart rates of 480 to 520 beats/min. Images
were recorded in all animals before surgical intervention, at 2 and 4 weeks
after banding, and at 1, 2, 3, and 4 weeks after removal of aortic constriction
(debanding). Two technicians blinded to the animals’ experimental status
performed examinations and measurements.
Tissue Procurement
At the time of death, hearts were rapidly excised, and the LV apices were
sectioned and flash-frozen in liquid nitrogen for gene array analysis. Addi-
tional animals allocated to histologic analysis were perfused with phos-
phate-buffered saline followed by 10% formalin, fixed overnight in
formalin, and then processed for histologic analysis with periodic acid–Schiff
staining.14 Cardiomyocyte cross-sectional area was measured with ImageJ
software (version 1.38j; National Institutes of Health, Bethesda, Md).15
RNA Preparation, MicroArray Process, and
Real-time Polymerase Chain Reaction
Semipooled groups of mice were created to minimize variation between
mice within a tested group and to enhance detection of variation between
experimental groups. For each experimental group, 9 mice were selected
from a group of up to 22 based on echocardiographic criteria of both pro-
gression with banding (increase in LV mass of>20%) and regression
with debanding (decrease in LV mass of>10%). Within these groups, sub-
groups of 3 animals were randomly pooled so that 3 samples would be
created for each experimental group.
LV apices were homogenized in 0.5 mL of ice-cold Trizol solution
(Sigma, St Louis, Mo) by using a bead mill homogenizer (Retsch, New-
town, Pa). RNA was then isolated with the standard Trizol procedure,
with additional steps for removal of DNA and fibrous tissue. Purity of
RNA was verified by using a 260/280 ratio of 1.95 or greater. An Agilent
(Santa Clara, Calif) BioAnalyzer 2100 instrument was used to verify
RNA integrity for all samples. Five hundred nanograms of total RNA was
labeled with Cyanine-5-CTP in a T-7 transcription reaction by using the
Agilent Low Input Linear RNA Amplification/Labeling System. Labeled
cRNA from samples was then hybridized to Agilent mouse 44k develop-
mental microarray slides in the presence of equimolar concentrations of
Cyanine-3-CTP–labeled mouse reference RNA prepared from pools of
1-day-old mouse pups. Real-time polymerase chain reaction (PCR) was
performed with Taqman primers and probes (Applied Biosystems Interna-
tional, Foster City, Calif).
Western Blotting
Protein fractions were isolated in ice-cold lysis buffer during Dounce
homogenization. Concentrations were determined by using the Bradford as-
say. Protein fractions were denatured in loading buffer. Thirty micrograms
of each sample was then loaded into alternating lanes for gel electrophoresis.
Membrane transfer was performed overnight, and rabbit anti-mouse anti-
body was used to probe for polo-like kinase 1 (Plk1) and hippocalin-like
1 (Hpcal1). Glyceraldehyde-3-phosphate dehydrogenase was used as the
loading control.
Statistical Methods
All physiologic data are presented as the mean  standard error, except
where noted. Real-time PCR data were log-transformed before comparison.
All comparisons of physiologic data were performed by using 2-tailed type
3 or type 1 t tests. Microarray data (n¼ 12 arrays) were less normalized, and
probes were filtered for features having a normalized intensity of less than
30 aFU in either red or green channels. Probes were removed if data were
not present in at least 9 of 12 samples. Missing data points were imputed
(to facilitate further statistical comparisons) by using the k nearest-neigh-
bors algorithm (k¼ 2). Samples were then standardized (m¼ 0, s¼ 1) usingardiovascular Surgery c Volume 137, Number 1 233
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ware, Inc, Vancouver, British Columbia, Canada). Differences in expressed
genes were validated by using significance analysis of microarrays with
a false discovery rate of 5%.
Linear models for microarray (Limma)16 was used to model the variation
in all data sets and perform the following contrasts: band versus sham, de-
band versus sham deband, and (deband sham deband) versus (band 
sham). These contrasts were executed by using custom scripts written in
the R statistical language and environment (R Version 2.2.1, build
r36812). Genes were identified as significant in each contrast with the crite-
ria of a P value of .01 or less and a mean fold change of 1.2 or greater.
Unsupervised gene and array clustering was performed for each compar-
ison: band versus sham, deband versus band, and deband versus sham de-
band. Data for each gene being compared were filtered for 3 instances of
a mean fold change of 2 or greater. Data were further adjusted by median
centering the genes. Average linkage hierarchic clustering with a centered
correlation similarity metric for both genes and arrays was performed
with Gene Cluster 3.0 (Michiel de Hoon, University of Tokyo, Human Ge-
nome Center, Tokyo, Japan). Data were then visualized with Java TreeView
(version 1.0.13).
Gene ontologies of significant genes in each contrast were identified by
using the National Institutes of Health–curated Database for Annotation,
Visualization, and Integrated Discovery (DAVID) 2007.17 To facilitate
interpretation of gene ontology, functional clustering was performed, and
results were rank ordered by using DAVID with enrichment analysis and
were further organized according to the number of genes in that cluster rel-
ative to the total number of genes identified within a particular contrast. The
primary advantage of the DAVID technique is its ability to take large lists of
genes and identify the biologic processes and functions that are most impor-
tant (within the set of significant genes) to the biologic phenomenon under
study. Orthogonal filtering of data sets was performed by using the Signifi-
canceAnalysis of Functional Expression (SAFE)18 with customR scripts. In
this method, also called orthogonal filtering, all genes are first organized
based on their gene ontologies or gene ontology categories. Each ontologic
category is then evaluated based on the degree of variation of individual
geneswithin that category, regardless of the significance of individual genes.
The more randomly the genes within each ontology are distributed, the less
likely that that ontology is contributing to the observed differences in the ex-
perimental groups. Ontologies are then ranked based on their relative signif-
icance to the process under study. Essentially, the entire gene array is used to
generate meaningful information about the process under study, rather than
just a few dozen genes that are identified as significantly different. Gene
ontologies with a P value of .1 or less were identified in all contrasts.
RESULTS
Regression of Pressure-induced LVH
Sixty mice were used in this study: 2 died perioperatively,
and 2 were excluded with wound infections. Our technique
of minimally invasive banding and debanding effectively
produced LVH with subsequent regression. Doppler veloc-
ity ratios between the right and left carotid arteries verified
creation and relief of arch obstruction, as previously demon-
strated.10 Grossly, heart weight/body weight ratios similarly
increased with banding and normalized after debanding
(Figure 1, A). Echocardiographically, aortic constriction re-
sulted in increased wall thickness, greater chamber dimen-
sions, and significantly greater LV mass (Figure 1, A, and
Table E1). One week after band removal, most parameters
changed in the direction of baseline, with a favorable trend
noted in fractional shortening. Histologically, cardiomyo-
cyte cross-sectional areas increased approximately 20%234 The Journal of Thoracic and Cardiovascular Surafter banding and decreased significantly after debanding
(Figure 1, B and C). Three common genetic expression
markers of ventricular hypertrophy were evaluated by using
real-time PCR, including b myosin heavy chain, natriuretic
peptide type B, and skeletal muscle a1-actin (n ¼ 6–8), to
determine the corresponding molecular changes. All were
significantly upregulated in the banded animals and normal-
ized in debanded mice. For example, natriuretic peptide
levels increased 65.4  25.4–fold with banding (sham, 1.0
 0.2–fold; P< .05) and decreased with debanding (2.9 
0.8, P<.05 vs banding). Taken together, these data compre-
hensibly demonstrate a reproducible model to study mecha-
nisms independently associated with LVH regression.
Identification and Clustering of Significant Genes
To minimize variation in for our array experiments, we
used echocardiography to select 9 animals from a larger
starting cohort of mice for each group (n¼ 11–22). The sen-
sitivity of the array technology demanded that we study the
best representative animals for each group. Furthermore, at
the time of these studies, it was cost-prohibitive to do indi-
vidual arrays for each animal. Nevertheless, changes in
LV mass index were not significantly different between
the full and array data sets (ie, D percentage Band [total,
n ¼ 17] 35.2%  4.3% compared with Band [array, n ¼
9] 42.6%  5.0% [P ¼ .29] and the D percentage Deband
[total, n ¼ 22] 9.8%  1.9% compared with Deband
[array, n¼ 9]15.1% 1.6% [P¼ .09]). After preliminary
filtering and standardization, a total of 14,693 distinct
transcripts were identified in our heart tissue and analyzed
with Limma. In the regression contrast (deband vs band)
we identified 255 differentially expressed genes: 92 were
upregulated, and 133 were downregulated. Contrasts for
LVH progression (band vs sham) and for the regressed state
(deband vs sham deband) identified 288 and 727 differen-
tially expressed genes, respectively (Figure 2, A). During
LVH progression, there were 158 upregulated and 130
downregulated genes, and in the deband versus sham deband
contrast there were 244 upregulated and 483 downregulated
(detailed profiles for each contrast provided in Table E2).
Interestingly, we identified only 23 genes that were signif-
icantly differentially expressed in both LVH progression and
regression. Conversely, 108 genes were distinctly associated
with regression. In examining the most differentially upre-
gulated genes in regression, there were 2 cell-cycle control
genes, Plk1 and midkine, a myosin peptide not previously
associated with the heart; the neural conduction protein
Hpcal1; and Pramef12, a protein with homology to a mela-
noma-associated protein (Figure 2, B). Of these, only mid-
kine has previously been associated with cardiovascular
disease.19 Western blot analysis confirmed the relationship
between our gene array and protein expression for Plk1
and Hpcal1 (Figure 2, C). Among the most downregulated
genes in regression, only the trends in natriuretic peptidegery c January 2009
Stansfield et al Cardiopulmonary Support and PhysiologyFIGURE 1. Physiologic and structural evidence of left ventricular hypertrophy reversal. A, Heart weight (HW)/body weight (BW) ratios (n ¼ 11–22 per
group) and serial echocardiographic measurements showing changes over the depicted time period (n ¼ 11–22 per group). B, Left ventricular (LV) cross-
sections stained with periodic acid–Schiff. C, Calculated cardiomyocyte cross-sectional areas (n ¼ 4 per group). *P< .05 versus the sham group,
yP< .05 versus the band group.C
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prior understanding of LVH, and changes in expression of
the remaining genes were unique to this experiment.
Although we identified changes in expression of individ-
ual genes, we sought to determine whether LVH regression
was associated with a distinct genomic pattern. Indeed, unsu-
pervised clustering of the samples in each comparison
showed clear separation of the band and sham groups and
of the deband and band groups (Figure 2, D). The separation
was less distinct in the deband versus sham deband compar-
ison, with 1 sample from the deband group and 1 sample
from the sham deband group not clustering appropriately.
This observation indicates that the expression patterns of
the deband and sham deband groups were less significant
thanmight otherwise have been predicted based on individualThe Journal of Thoracic and Cgene differences originally identified by means of Limma.
Taken together, the global expression pattern depicted in
the unsupervised clustering suggests that differences be-
tween groups were not limited to a few hundred genes but
rather to several thousand, and those differences were consis-
tent from one group of animals to another.
Gene Expression Profiles Associated With LVH
Regression
In the LVH progression analysis gene ontology clustering
of our most significant genes showed expected characteris-
tics of hypertrophic stress, including a large focus on actin,
microtubules, cytoskeletal integrity, and contractile func-
tion, with the remainder including organelle production,
transport, and organization (Table 1 and see Figure E1).ardiovascular Surgery c Volume 137, Number 1 235
Cardiopulmonary Support and Physiology Stansfield et al
C
S
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mental contrast (P< .01 and absolute fold change>1.2). B, Most differentially expressed genes in the regression contrast (deband vs band). C, Western
Blot for selected proteins identified in the deband versus band comparison. D, Unsupervised gene clustering between groups. B, Band; S, sham; DB, deband;
SDB, sham deband.Similarly designed gene array studies of LVH progression
(in mice) have identified these same genomic themes.5 In
the regression analysis none of these cytoskeletal or contrac-
tile clusters were differentially expressed. Instead, there was
a predominance of intracellular and extracellular signaling
themes. Further breakdown of the functional clusters in-
volved in the regression process indicated that cell growth,
morphogenesis, and cell cycle were all highly upregulated,
whereas metabolism and protein and nucleotide production
were downregulated. Lastly, the regressed state (deband vs
TABLE 1. Gene ontology clustering of significant genes between
respective groups, as assessed by using the DAVID 2007 technique
and listed in order of prevalence
Band vs sham Deband vs band
Deband vs
sham deband
Organelle production Protein glycosylation Cellular metabolism
Intracellular transport Extracellular signaling Protein metabolism
Actin/cytoskeletal
organization
Glycosaminoglycan
binding
Organelle
organization
Contractile protein binding Cell adhesion Intracellular transport
Nucleotide binding Cell-cycle control Ion binding236 The Journal of Thoracic and Cardiovascular Sursham deband) had 126 overlapping genes that demonstrated
mostly activity in metabolism and in mitochondria and other
organelles. This is markedly different from the patterns asso-
ciated with either LVH progression or regression. This latter
observation suggests that although the debanded hearts ap-
pear structurally similar to the sham-debanded hearts, they
remain genomically distinct.
We next evaluated all 14,693 expressed genes using the
orthogonal filtering methodology SAFE to identify signifi-
cant gene ontologies and gene set enrichment analysis cate-
gories that were relevant to the processes of both LVH
progression and LVH regression. The SAFE analysis is par-
ticularly useful because it gathers information from all genes
in the experiment and not merely ontologies characterized
by statistically significant genes. In regression, there were
52 gene ontologies and 34 gene set enrichment analysis cat-
egories with a P value of .1 or less (Table E3). Importantly,
only 5 gene ontologies were identified as common to both
LVH progression and regression (Table E4). These data fur-
ther distinguish LVH regression as an independent process.
Taken together, the DAVID and SAFE ontologic analyses
corroborate differences identified at the individual gene levelgery c January 2009
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a distinct thematic pattern of gene expression.
DISCUSSION
Our results compare favorably with those of a recently
published study that detailed gene expression by means of
microarray in rats after transverse arch debanding.12 Al-
though they identified 52 regression-related genes, animals
that underwent an operation 2 weeks before heart procure-
ment were compared with animals 24 hours after reoperative
chest surgery to remove an inflammatory silk band. Thus
many transcripts might actually reflect differences attributed
to the perioperative systemic inflammatory response. We
purposefully and rigorously designed (cage strategy and cir-
cadian cycling of procedures) our study in a minimally inva-
sive murine model to avoid confounding perioperative
variables. Furthermore, no quantifiable physiologic data are
reported to indicate that LVH regression actually occurred.
Additionally, statistical issues evaluating fold changes be-
tween groups (differences are expressed in relation to a single
sham control group and not between the contrasting groups)
are magnified when the essential comparison only used 3 an-
imals, as opposed to 9 animals in each of our groups. Finally,
their study used a limited array platformwith less than 10,000
transcripts, possibly limiting their scope of observation, es-
pecially when compared with the whole-genome platform
used in our present study.
Hypertrophy and atrophy have similarly been studied in
skeletal muscle, and the processes have much in common
with the progression and regression of LVH. For example, at-
rophy has been previously demonstrated to be an active pro-
cess with a distinct pattern of gene expression rather than
simply the genomic reverse ofmuscle hypertrophy.20,21 Func-
tional genes associated with atrophy and regression involve
increased protein degradation, downregulation of adenosine
triphosphate production, decreased glycolysis, a decrease in
growth protein synthesis, and altered extracellular matrix pro-
duction, all categories that we identified in regression com-
pared with LVH. Fundamentally, however, muscle atrophy
typically describes progression to a disease state, whereas re-
gression of LVH is a return to a normal physiologic state. In
this regard, and because of the intrinsic physiologic differ-
ences between skeletal and cardiac muscle, we believe that
mechanistic inferences must be limited in all but the final
pathways that directly result in decreased muscle mass.
Our results must be viewed with several caveats. In this
study we have examined in detail the effects of banding at
only 1 time point (4 weeks) and for only a discreet period
of pressure unloading (1 week). We suspect that the influ-
ence of pressure relief when the ventricle is either less (2–
3 weeks of banding) or more (6 weeks of banding) stressed
would offer different structural and genomic patterns. We
thus are likely witnessing a continuum of change as the heart
both negatively and positively remodels. We chose to orga-The Journal of Thoracic andnize the array around the 1-week time point because our pre-
liminary data indicated that the effective physiologic and
structural reversal of LVH was nearly complete at this
time (and far enough away from the surgical procedure), de-
spite differences in gene expression. As demonstrated sim-
ply in the Venn diagram, structural reversal did not create
a ‘‘normal heart,’’ as assessed genomically. These observa-
tions will propel more detailed studies focusing on timing
and better understanding of the reversed state. Finally, we
acknowledge that this model is really a model that relieves
acute pressure overload (banding). Thus parallels to the in-
sidious pressure overload that occurs with typical aortic ste-
nosis in human subjects and its subsequent reversal with
aortic valve replacement13,22 can only be inferred.
In conclusion, we demonstrate that relief of pressure over-
load–induced LVH is not simply the reverse of LVH pro-
gression but rather a unique process with a specific gene
expression profile. Therapeutic approaches to LVH based
on enhancing regression, rather than impeding progression,
are rarely pursued. Elaborating mechanisms associated with
both regression and the regressed state have great potential
for identifying novel and clinically relevant strategies for
treating patients with LVH.
Clinical Implications
Much attention is given to the study of mechanisms in-
volved with the development of LVH and heart failure. Un-
fortunately, current strategies have not markedly altered the
natural history of this disease. Aortic valve replacement for
severe aortic stenosis (ie, removing the band) has clearly
demonstrated a favorable effect in cardiac remodeling. Yet
there is a large subset of patients with LVH from pressure
overload that do not regress and have increased risk of car-
diovascular morbidity and mortality. Although an allure ex-
ists to jump to elaborate therapies for heart failure (eg,
cellular replacement and stem cell injections), a great need
exists to identify the underlying mechanisms associated
with myocardial recovery that can subsequently be targeted
for sole therapy or perhaps in combination with mechanical
unloading (aortic valve replacement or ventricular assist).
Although LVH experimentation in mice is temporally quite
different from that in human subjects, it is nonetheless an im-
portant first step in characterizing the genomic signature as-
sociated with cardiac remodeling and will enhance future
work in myocardial recovery therapy.
We thank Monte Willis, MD, PhD, for his critical comments;
David Threadgill, PhD, for his assistance with experimental design
and interpretation; and Margaret Alford Cloud for her editorial as-
sistance.
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Surgical Model and Experimental Design
In accordance with an institutionally approved Institutional Animal Care
and Use Committee protocol, 10-week-old C57Bl6 male mice were ran-
domly assigned to one of 4 groups: sham, band, sham deband, and deband.
Mice in the sham and band groups underwent minimally invasive transverse
aortic banding. The only difference between the 2 groups was that in the
sham group the constrictive band was placed but not tightened. Adequate
placement of the band was verified by means of evaluation of carotid Dopp-
ler scans both before and after placement of the aortic band. Adequate band-
ing was accepted when the Doppler velocity ratio doubled from the right to
left carotid arteries. Animals in the deband and sham deband groups had ini-
tial procedures identical to those for the band and sham groups, respectively.
At 4 weeks, the aortic band was removed, heretofore referred to as deban-
ded.E1 Debanding efficiency was verified bymeans of carotid Doppler scan-
ning with normalization of carotid velocities. Deband and sham deband
animals were killed 1 week after the deband procedure for all evaluations
except histology, in which animals were killed both at 1 and 4 weeks after
debanding.
Semipooled groups of mice were created to minimize variation between
mice within a tested group and to enhance detection of variation between
experimental groups. For each experimental group, 9 mice were selected
from a group of up to 22 based on echocardiographic criteria of LVH rever-
sal. Within these groups, subgroups of 3 animals were pooled so that 3 sam-
ples would be created for each experimental group.
Tissue Procurement
At the time of death, hearts were rapidly excised, and the left ventricular
apices were sectioned and flash-frozen in liquid nitrogen for gene array anal-
ysis. Additional animals allocated to histologic analysis were perfused with
PBS followed by 10% formalin, fixed overnight in formalin, and then pro-
cessed for histologic analysis by using periodic acid–Schiff staining. Cardi-
omyocyte cross-sectional area was measured with ImageJ software (version
1.38j).E2
Transthoracic Echocardiography
Transthoracic echocardiography was performed with the Vevo 660 High
Resolution Biomicroscopy System equipped with a 30-Mhz transducer (Vi-
sual Sonics). During examination, mice were anesthetized with 1% to 1.5%
inhaled isoflurane. Depth of anesthesia was standardized by recording im-
ages at heart rates of 480 to 520 beats/min. Images were recorded in all an-
imals before surgical intervention, at 2 and 4 weeks after banding, and at 1,
2, 3, and 4 weeks after removal of aortic constriction (debanding). Two tech-
nicians, blinded to the animals’ experimental status, performed examina-
tions and measurements.
RNA Preparation, MicroArray Process, and Real-
time PCR
LV apices were homogenized in 0.5 mL of ice-cold Trizol solution
(Sigma) with a bead mill homogenizer (Retsch). RNA was then isolated
with the standard Trizol procedure, with additional steps for removal of
DNA and fibrous tissue. Purity of RNA was verified by using a 260/280 ra-
tio of 1.95 or greater. An Agilent BioAnalyzer 2100 instrument was used to
verify RNA integrity for all samples. Five hundred nanograms of total RNA
was labeled with Cyanine-5-CTP in a T-7 transcription reaction by using the
Agilent Low Input Linear RNA Amplification/Labeling System. Labeled
cRNA from samples was then hybridized to Agilent mouse 44k develop-
mental microarray slides in the presence of equimolar concentrations of
Cyanine-3-CTP–labeled mouse reference RNA prepared from pools ofThe Journal of Thoracic and Car1-day-old mouse pups. Real-time PCR was performed by using Taqman
primers and probes (Applied Biosystems International).
Statistical Methods
All physiologic data are presented as the mean  standard error, except
where noted. Real-time PCR data were log transformed before comparison.
All comparisons of physiologic data were performed by using 2-tailed type
3 or type 1 t tests. Microarray data (n¼ 12 arrays) were LOESS normalized,
and probes were filtered for features having a normalized intensity of less
than 30 aFU in either red or green channels. Probes were removed if data
were not present in at least 9 of 12 samples. Missing data points were im-
puted (to facilitate further statistical comparisons) by using the k nearest
neighbors algorithm (k ¼ 2). Samples were then standardized (m ¼ 0,
d¼ 1) by using a custom Perl script (ActiveState Perl 5.8.1, build 807). Dif-
ferences in expressed genes were validated by using significance analysis of
microarrays, with a false discovery rate of 5%.
LimmaE3 was used to model the variation in all data sets and perform the
following contrasts: band versus sham, deband versus sham deband, and
(deband sham deband) versus (band sham). These contrasts were exe-
cuted by using custom scripts written in the R statistical language and envi-
ronment (Version 2.2.1, build r36812, release date 2005-12-20.). Genes
were identified as significant in each contrast with the criteria of a P value
of .01 or less and a mean fold change of 1.2 or greater.
Unsupervised gene and array clustering was performed for each compar-
ison: band versus sham, deband versus band, and deband versus sham de-
band. Data for each gene being compared were filtered for 3 instances of
a mean fold change of 2 or greater. Data were further adjusted by median
centering the genes. Average linkage hierarchic clustering with a centered
correlation similarity metric for both genes and arrays was performed by us-
ing Gene Cluster 3.0. (Michiel de Hoon, University of Tokyo, Human Ge-
nome Center, 2006). Data were then visualized with Java TreeView
software (version 1.0.13).
Ontologies of significant genes in each contrast were identified by using
DAVID 2007.E4 Functional clustering was performed to facilitate interpre-
tation of gene ontology results, and functional clusters were rank ordered by
using DAVID with enrichment analysis and were further organized accord-
ing to the number of genes in that cluster relative to the total number of
genes identified within a particular contrast.
Orthogonal filtering of data sets was performed with SAFEE5 by using
custom R scripts. Briefly, this test evaluates the significance of a given
gene ontology relative to the comparison being studied by using the normal-
ity of distribution of all the genes (within that ontology) that are identified
within the data set, regardless of the significance of individual genes. All
gene ontologies with a P value of .1 or less were identified in all contrasts.
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Stansfield et al Cardiopulmonary Support and PhysiologyTABLE E1. Echocardiographic measurements at each time point for each of the experimental groups
Sham Band Sham deband Deband
Baseline
IVSd (mm) 0.63  0.02 0.57  0.02 0.66  0.02 0.56  0.02
LVIDd (mm) 4.2  0.06 4.23  0.08 4.12  0.08 4.14  0.06
LVPWd (mm) 0.56  0.02 0.57  0.02 0.6  0.02 0.56  0.02
IVSs (mm) 0.69  0.02 0.67  0.02 0.73  0.02 0.64  0.02
LVIDs (mm) 3.22  0.09 3.16  0.08 3.15  0.13 3.13  0.1
LVPWs (mm) 0.71  0.02 0.73  0.03 0.72  0.03 0.69  0.01
LVFS (%) 23.1  1.2 25  1.8 23.5  1.9 23.9  1.9
LVEF (%) 46.6  2.1 49.5  2.7 47  3.2 47.7  3.2
LVMass (mg), uncorrected 90.9  4 87.8  2.7 92.9  2.1 83.4  2.8
LVMass (mg), corrected 72.7  3.2 70.2  2.2 74.3  1.7 66.7  2.2
4 wk Banded
IVSd (mm) 0.62  0.02 0.72  0.02* 0.66  0.02 0.66  0.02*
LVIDd (mm) 4.23  0.14 4.47  0.09* 4.19  0.07 4.44  0.07*
LVPWd (mm) 0.58  0.02 0.67  0.02* 0.59  0.01 0.62  0.01*
IVSs (mm) 0.68  0.02 0.78  0.02* 0.74  0.02 0.73  0.02*
LVIDs (mm) 3.23  0.16 3.58  0.15* 3.23  0.11 3.54  0.11*
LVPWs (mm) 0.71  0.03 0.84  0.04* 0.74  0.03 0.77  0.02*
LVFS (%) 23.6  1.7 20.7  2.3* 23.4  1.5 19.8  1.8*
LVEF (%) 47.1  3 41.7  3.7* 46.9  2.4 40.4  3.1*
LVMass (mg), uncorrected 92.9  5.5 125  4.9* 97  1.8 109.9  3*
LVMass (mg), corrected 74.3  4.4 100  3.9* 77.6  1.4 87.9  2.4*
1 wk Debanded
IVSd (mm) 0.69  0.02 0.58  0.02y
LVIDd (mm) 4.23  0.06 4.37  0.08y
LVPWd (mm) 0.58  0.01 0.58  0.01y
IVSs (mm) 0.73  0.02 0.66  0.02y
LVIDs (mm) 3.28  0.07 3.47  0.13y
LVPWs (mm) 0.72  0.02 0.69  0.02y
LVFS (%) 21.3  1.2 20.3  1.6
LVEF (%) 43.5  2.1 41.4  2.8
LVMass (mg), uncorrected 100.8  2.2 94  3.7y
LVMass (mg), corrected 80.6  1.8 75.2  3y
IVSd, Interventricular septum in diastole; LVIDd, left ventricular internal diameter in diastole; LVPWd, left ventricular posterior wall in diastole and systole; IVSs, interventricular
septum in diastole and systole; LVIDs, left ventricular internal diameter in diastole and systole; LVPWs, left ventricular posterior wall in systole; LVFS, left ventricular fractional
shortening; LVEF, left ventricular ejection fraction; LVMass, Left ventricular mass. *P< .05 versus baseline. yP< .05 versus 4 weeks banded.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 1 238.e3
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PTABLE E2. A. Genes most differentially expressed in each comparison: Deband versus band groups
Direction (deband) Accession no. Symbol Name Fold D
þ NM_030679 Myh1 Myosin, heavy polypeptide 1, skeletal muscle, adult 2.742
þ U01063 Plk1 Polo-like kinase 1 (Drosophila) 2.475
þ NM_016677 Hpcal1 Hippocalcin-like 1 2.074
þ NM_001012336 Mdk Midkine 2.044
þ NM_029948 Pramef12 PRAME family member 12 1.979
þ NM_147089 Olfr572 Olfactory receptor 572 1.978
þ AK036567 Mgat5 Mannoside acetylglucosaminyltransferase 5 1.962
þ AK083490 Arfrp1 Adenosine diphosphate–ribosylation
factor–related protein 1
1.916
þ NM_009303 Syngr1 Synaptogyrin 1 1.845
þ NM_182991 5330410G16R RIKEN cDNA 5330410G16 gene 1.730
þ NM_172817 Zfp647 Zinc finger protein 647 1.713
þ NM_007472 Aqp1 Aquaporin 1 1.673
þ AC124532 Calcoco1 Calcium binding and coiled coil domain 1 1.638
þ NM_146201 Zfp553 Zinc finger protein 553 1.628
þ NM_001002272 Tro Trophinin 1.626
þ NM_011601 Tlm T lymphoma oncogene 1.596
þ NM_007444 Amd2 S-adenosylmethionine decarboxylase 2 1.550
þ AC155922 Rps6ka5 Ribosomal protein S6 kinase, polypeptide 5 1.538
þ XM_925008 Slc44a5 Solute carrier family 44, member 5 1.538
þ AC161037 Hnrpul1 Heterogeneous nuclear ribonucleoprotein
U-like 1
1.530
 NM_020581 Angptl4 Angiopoietin-like 4 2.550
 NM_008725 Nppa Natriuretic peptide precursor type A 2.052
 XM_621314 Dsp Desmoplakin 1.928
 XM_283556 Fer1l3 Fer-1-like 3, myoferlin (C elegans) 1.758
 NM_001013390 Scn4b Sodium channel, type IV, b 1.701
 NM_021453 Pga5 Pepsinogen 5, group I 1.651
 NM_024478 Grpel1 GrpE-like 1, mitochondrial 1.645
 NM_053176 Hrg Histidine-rich glycoprotein 1.625
 NM_019662 Rrad Ras-related associated with diabetes 1.623
 NM_171826 Cldnd1 Claudin domain containing 1 1.614
 NM_133786 Smc4 Structural maintenance of chromosomes 4 1.607
 NM_023733 Crot Carnitine O-octanoyltransferase 1.605
 AC1017091 Lama2 Laminin, a 2 1.601
 NM_029977 Polq Polymerase (DNA directed), theta 1.592
 NM_134072 Akr1c14 Aldo-keto reductase family 1, member C14 1.585
 NM_012037 Vat1 Vesicle amine transport protein 1 homolog 1.584
 NM_145406 Slc10a3 Solute carrier family 10, member 3 1.576
 NM_175277 Bola3 BolA-like 3 (E coli) 1.555
 NM_008961 Pter Phosphotriesterase related 1.554
 NM_008937 Prox1 Prospero-related homeobox 1 1.551238.e4 The Journal of Thoracic and Cardiovascular Surgery c January 2009
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Direction Accession no. Symbol Name Fold D
þ XM_001002752 Zc3h7b Zinc finger CCCH type containing 7B 1.884
þ NM_008725 Nppa Natriuretic peptide precursor type A 1.754
þ NM_007489 Arntl Aryl hydrocarbon receptor nuclear translocator-like 1.645
þ NM_013468 Ankrd1 Ankyrin repeat domain 1 (cardiac muscle) 1.557
þ NM_015784 Postn Periostin, osteoblast-specific factor 1.534
þ AC034265 Ankrd23 Ankyrin repeat domain 23 1.530
þ NM_134129 Prpf19 PRP19/PSO4 pre-mRNA processing factor 19 homolog 1.497
þ NM_133357 Krt75 Keratin 75 1.480
þ NM_010480 Hsp90aa1 Heat shock protein 90 kd a, class A member 1 1.454
þ NM_031260 Mov10l1 Moloney leukemia virus 10-like 1 1.445
þ NM_021453 Pga5 Pepsinogen 5, group I 1.445
þ NM_009221 Snca Synuclein, a 1.439
þ NM_007564 Zfp36l1 Zinc finger protein 36, C3H type-like 1 1.424
þ NM_172621 Clic5 Chloride intracellular channel 5 1.414
þ NM_133744 Ccdc71 Coiled-coil domain containing 71 1.413
þ NM_178701 Lrrc8d Leucine-rich repeat containing 8D 1.410
þ NM_009007 Rac1 RAS-related C3 botulinum substrate 1 1.394
þ NM_173442 Gcnt1 Glucosaminyl (N-acetyl) transferase 1, core 2 1.388
þ NM_029614 Prss23 Protease, serine, 23 1.378
þ NM_008524 Lum Lumican 1.365
 NM_007606 Car3 Carbonic anhydrase 3 2.672
 NM_030679 Myh1 Myosin, heavy polypeptide 1, skeletal muscle, adult 2.131
 NM_010005 Cyp2d10 Cytochrome P450, family 2, subfamily d, polypeptide 10 2.051
 NM_009416 Tpm2 Tropomyosin 2, b 2.016
 U01063 Plk1 Polo-like kinase 1 (Drosophila) 1.982
 NM_017370 Hp Haptoglobin 1.971
 NM_147089 Olfr572 Olfactory receptor 572 1.925
 NM_001012336 Mdk Midkine 1.911
 NM_011066 Per2 Period homolog 2 (Drosophila) 1.867
 BC004722 Malat1 Metastasis-associated lung adenocarcinoma
transcript 1 (noncoding RNA)
1.859
 NM_013900 Mfi2 Antigen p97 (melanoma associated) 1.727
 NM_010404 Hap1 Huntingtin-associated protein 1 1.627
 NM_177709 Tusc5 Tumor suppressor candidate 5 1.597
 XM_981394 Rhobtb1 Rho-related BTB domain containing 1 1.586
 AK083490 Arfrp1 Adenosine diphosphate-ribosylation factor related protein 1 1.567
 NM_016693 Map3k6 Mitogen-activated protein kinase kinase kinase 6 1.562
 NM_009920 Cnih2 Cornichon homolog 2 (Drosophila) 1.549
 NM_025866 Cdca7 Cell division cycle associated 7 1.534
 NM_001025156 Ccdc93 Coiled-coil domain containing 93 1.524
 NM_009119 Sap18 Sin3-associated polypeptide 18 1.520The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 1 238.e5
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Direction Accession no. Symbol Name Fold D
þ NM_133777 Ube2s Ubiquitin-conjugating enzyme E2S 1.967
þ AK036567 Mgat5 Mannoside acetylglucosaminyltransferase 5 1.731
þ NM_029948 Pramef12 PRAME family member 12 1.704
þ NM_011202 Ptpn11 Protein tyrosine phosphatase, nonreceptor type 11 1.620
þ NM_144791 Tor1aip1 Torsin A interacting protein 1 1.507
þ AB009392 Hnrpl Heterogeneous nuclear ribonucleoprotein L 1.505
þ NM_010890 Nedd4 Neural precursor cell, developmentally downregulation gene 4 1.501
þ NM_028004 Ttn Titin 1.497
þ NM_001024955 Pik3r1 Phosphatidylinositol 3-kinase, reg. sub., polypeptide 1 1.496
þ NM_008609 Mmp15 Matrix metallopeptidase 15 1.492
þ NM_146087 Csnk1a1 Casein kinase 1, a 1 1.483
þ NM_173364 Zfp445 Zinc finger protein 445 1.480
þ NM_025403 Nola3 Nucleolar protein family A, member 3 1.472
þ NM_152134 Homer1 Homer homolog 1 (Drosophila) 1.469
þ NM_011601 Tlm T lymphoma oncogene 1.466
þ NM_009652 Akt1 Thymoma viral proto-oncogene 1 1.464
þ NM_146201 Zfp553 Zinc finger protein 553 1.464
þ NM_173028 Vps13a Vacuolar protein sorting 13A (yeast) 1.464
þ NM_008714 Notch1 Notch gene homolog 1 (Drosophila) 1.447
þ NM_029657 Mgrn1 Mahogunin, ring finger 1 1.445
 NM_020581 Angptl4 Angiopoietin-like 4 1.875
 NM_001013390 Scn4b Sodium channel, type IV, b 1.744
 XM_001001760 Gan Giant axonal neuropathy 1.671
 NM_145741 Gdf10 Growth differentiation factor 10 1.651
 NM_178882 D2hgdh D-2-hydroxyglutarate dehydrogenase 1.578
 NM_012037 Vat1 Vesicle amine transport protein 1 homolog 1.572
 XM_001006025 Rpl19 Ribosomal protein L19 1.558
 NM_010937 Nras Neuroblastoma ras oncogene 1.553
 NM_008937 Prox1 Prospero-related homeobox 1 1.540
 XM_915717 Ube2e1 Ubiquitin-conjugating enzyme E2E 1, UBC4/5 homolog 1.539
 XR_001538 Tfb2m Transcription factor B2, mitochondrial 1.527
 NM_053176 Hrg Histidine-rich glycoprotein 1.524
 NM_025276 Evpl Envoplakin 1.520
 AK041640 Zfpn1a4 Zinc finger protein, subfamily 1A, 4 (Eos) 1.517
 NM_019794 Dnaja2 DnaJ (Hsp40) homolog, subfamily A, member 2 1.516
 XM_621314 Dsp Desmoplakin 1.514
 NM_027777 Pex1 Peroxisome biogenesis factor 1 1.505
 NM_007666 Cdh6 Cadherin 6 1.502
 NM_133786 Smc4 Structural maintenance of chromosomes 4 1.501
 NM_012010 Eif2s3x Eukaryotic translation initiation factor 2, subunit 3 1.491238.e6 The Journal of Thoracic and Cardiovascular Surgery c January 2009
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LVH progression)
GO categories GSEA categories
GO:0015629 Actin cytoskeleton Actin pathway
GO:0007411 Axon guidance Adrenergic
GO:0003824 Catalytic activity Akt pathway
GO:0006968 Cellular defense response Alk pathway
GO:0004197 Cysteine-type endopeptidase activity Bcl2 family and reg network
GO:0004519 Endonuclease activity Carm-er pathway
GO:0005789 Endoplasmic reticulum membrane Cell cycle
GO:0016251 RNA polymerase II transcription factor Creb pathway
GO:0004364 Glutathione transferase activity Death pathway
GO:0006811 Ion transport Differentiation pathway in PC12 cells
GO:0007254 JNK cascade Erk5 pathway
GO:0000287 Magnesium ion binding G a I pathway
GO:0006120 Mitochondrial electron transport,
NADH to ubiquinone
Glutamine down
GO:0005554 Molecular function unknown il2rb pathway
GO:0008137 NADH dehydrogenase (ubiquinone) IL-4 receptor in B lymphocytes
GO:0003954 NADH dehydrogenase activity INS
GO:0045786 Negative regulation of cell cycle IL-4 pathway
GO:0009968 Negative regulation signal transduction MAPK pathway
GO:0030182 Neuron cell differentiation Monocyte pathway
GO:0005643 Nuclear pore mRNA processing
GO:0000786 Nucleosome mRNA splicing
GO:0005634 Nucleus mtor pathway
GO:0016491 Oxidoreductase activity p53 hypoxia pathway
GO:0003755 Peptidyl-prolyl cis-transisomerase p53 signaling
GO:0007204 Positive regulation of cytosolic [Caþþ] Phosphoinositide-3-kinase pathway
GO:0006470 Protein amino acid dephosphorylation PIP3 signaling in B lymphocytes
GO:0006412 Protein biosynthesis Protein modification
GO:0006457 Protein folding Ptdins pathway
GO:0004722 Protein serine/threonine phosphatase Pyruvate metabolism
GO:0004725 Protein tyrosine phosphatase activity Rarrxr pathway
GO:0016567 Protein ubiquitination RNA polymerase
GO:0015992 Proton transport Stress pathway
GO:0008217 Regulation of blood pressure Tid pathway
GO:0042127 Regulation of cell proliferation Wnt pathway
GO:0006446 Regulation of translational initiation
GO:0006950 Response to stress
GO:0005840 Ribosome
GO:0003723 RNA binding
GO:0008380 RNA splicing
GO:0006814 Sodium ion transport
GO:0030528 Transcription regulator activity
GO:0003743 Translation initiation factor activity
GO:0006512 Ubiquitin cycle
GO:0000151 Ubiquitin ligase complex
GO:0006511 Ubiquitin-dependent protein catabolism
GO:0004842 Ubiquitin-protein ligase activity
GO:0030018 Z disc
GO:0008270 Zinc ion binding
GSEA, Gene set enrichment analysis; SAFE, Significance Analysis of Functional Expression; LVH, left ventricular hypertrophy; GO, gene ontology.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 1 238.e7
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GO:0005516 Calmodulin binding
GO:0003677 DNA binding
GO:0005874 Microtubule
GO:0005762 Mitochondrial large ribosomal subunit
GO:0003704 Specific RNA polymerase II transcription factor activity
GO:0004221 Ubiquitin thiolesterase activity
GSEA, Gene set enrichment analysis; SAFE, Significance Analysis of Functional Expression; LVH, left ventricular hypertrophy; GO, gene ontology.238.e8 The Journal of Thoracic and Cardiovascular Surgery c January 2009
